Abstract
Fast development of COVID-19 vaccines likely averted millions of deaths. We estimate how many more lives could have been saved if safe and effective vaccines were available earlier in the pandemic, in particular, before the epidemic waves in winter of 2020. We fit an epidemiological model informed by retrospective data and simulate counterfactual vaccination scenarios for the United Kingdom and the United States in which vaccines are available between 30 and 90 days earlier. We find that up to 1 July 2021 reductions in mortality range from 10,000 to 48,000 in the UK and 53,000 to 130,000 in the US, depending on when vaccinations start. This corresponds to a maximum of 7.1 and 4 deaths averted per 10,000 people in the UK and US respectively, or a reduction in overall deaths of 50% and 32%. We find that our model is sensitive to uncertain vaccine parameters and benefits depend on the time horizon of the analysis. However, the large average reductions we estimate suggests that it is highly cost-effective to make large investments in strategies to expedite vaccine availability.
Competing Interest Statement
Witold Wiecek has consulted for many pharmaceutical companies, including many of those developing COVID-19 vaccines.
Funding Statement
1Day Sooner funded all paid work on this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This epidemiological model did not use any non-public data or involve patients. All descriptions and modelling in this paper use data from the dataset introduced by Dong et al. (2020). Additionally, for alternative modelling specification we use excess mortality data from Solstad (2023). Dong Ensheng, Du Hongru, Gardner Lauren. An interactive web-based dashboard to track COVID-19 in real time. V 2020. Solstad SU. The Pandemics True Death Toll. III 2023.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revised version includes improved writing within the appendices, and addresses some mistakes within the text based on reader feedback, as well as improving the clarity of all figures.
↵21 This is an estimate based on Pfizer producing 2.5 times more than Moderna in 2020 but getting faster approval and running at full speed longer.
Data Availability
All data produced in the present work are available upon reasonable request to the authors.
